Empagliflozin stabilizes electrical activity in failing heart cells
Three-hour pretreatment with empagliflozin reduced multiple electrophysiological signs of arrhythmia in isolated mouse and rabbit heart cells from two non-ischemic ...
Three-hour pretreatment with empagliflozin reduced multiple electrophysiological signs of arrhythmia in isolated mouse and rabbit heart cells from two non-ischemic ...
A multicentre target trial emulation associated finerenone plus empagliflozin with a 52% reduction in albuminuria at 180 days in matched ...
A new study links SGLT2 inhibitor therapy with reduced circulating activin A, improved right-heart function, and modulation of BMP/activin signaling ...
A six-month multicenter study of 952 Pakistani adults found empagliflozin, alone or with metformin, significantly improved HbA1c, weight, and blood ...
A pooled analysis of two placebo-controlled crossover trials shows that the SGLT-2 inhibitors empagliflozin and dapagliflozin modestly but significantly raise ...
New evidence shows SGLT2 inhibitors protect the failing heart by directly activating PANK1 to restore coenzyme A biosynthesis and myocardial ...
New research shows the diabetes drug empagliflozin protects against experimental abdominal aortic aneurysm by reshaping the gut microbiome and strengthening ...
A retrospective study of 330 patients with type 2 diabetes found that long-term use of SGLT-2 inhibitors empagliflozin and dapagliflozin ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine